[Skip to Navigation]
Citations 0
April 2011

Dopamine Agonists vs Levodopa in Impulse Control Disorders—Reply

Author Affiliations

Author Affiliations: Departments of Psychiatry (Dr Weintraub) and Neurology (Dr Siderowf), University of Pennsylvania School of Medicine, Philadelphia; Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania (Dr Weintraub); Boehringer Ingelheim Pharma GmBH & Co, Ingelheim, Germany (Dr Fraessdorf); Department on Psychiatry, Yale University School of Medicine, New Haven, Connecticut (Dr Potenza); Department of Neurology, Duke University Medical Center, Durham, North Carolina (Dr Stacy); University of Cambridge, Cambridge, England (Dr Voon); Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, Connecticut (Dr Whetteckey); Boehringer Ingelheim (Canada) Ltd, Burlington, Ontario, Canada (Dr Wunderlich); and the Department of Neurology, University of Toronto, Toronto, Ontario, Canada (Dr Lang).

Arch Neurol. 2011;68(4):544-546. doi:10.1001/archneurol.2011.42

In reply

We appreciate the interest and comments by Grosset and colleagues regarding our study on the frequency and correlates of ICDs in Parkinson disease. The authors note that in patients who did not take a DA or levodopa, disease duration was likely shorter, reducing their cumulative risk for developing ICDs. Indeed, this patient subset (n = 59) had shorter disease duration than the rest of the study population (median [interquartile range] disease duration, 3.37 [2.37-6.06] years). However, given that disease duration was not associated with ICDs in the entire study population, a possible explanation for the low frequency (1.7%) of ICDs in this group is absence of treatment with dopaminergic therapy at the time of study assessment. Longitudinal studies could investigate this topic directly.

Add or change institution